Evaluating Regorafenib/Pembrolizumab in Refractory MSS-CRC
Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.
Afsaneh Barzi, MD, PhD, director, Employer Strategy (AccessHope); associate professor, Department of Medical Oncology & Therapeutics Research at City of Hope, explained the rationale for the phase 1/2 study of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer (MSS-CRC).
Transcription:
0:08 | In patients with microsatellite stable colorectal cancer immunotherapy has not been shown to be beneficial or effective. And therefore there is a search for appropriate combinations that can make basically the patients or the two more sensitive to immunotherapy.
0:27 | One of the combinations that has been high on the list is the combination of VEGF inhibitors and immunotherapy. Regorafenib is a multi-kinase inhibitor with a significant effect on VEGF or two which is a receptor to and given that it has single-agent activity in colorectal cancer. It seems like a very promising combination to look at the regorafenib plus pembrolizumab as a potential mechanism to overcome the resistance to pembrolizumab alone in patients with MSS colorectal cancer.
Guideline Spotlights Early-Line Agents for GEP-NETs
November 29th 2023New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.
Read More
